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Abstract
Objective
To evaluate the role of the copy number loss in SFMBT1 in a Caucasian population.
Methods
Five hundred sixty-seven Finnish and 377 Norwegian patients with idiopathic normal pressure
hydrocephalus (iNPH) were genotyped and compared with 508 Finnish elderly, neurologically
healthy controls. The copy number loss in intron 2 of SFMBT1 was determined using quan-
titative PCR.
Results
The copy number loss in intron 2 of SFMBT1was detected in 10% of Finnish (odds ratio [OR]
= 1.9, p = 0.0078) and in 21% of Norwegian (OR = 4.7, p < 0.0001) patients with iNPH
compared with 5.4% in Finnish controls. No copy number gains in SFMBT1 were detected in
patients with iNPH or healthy controls. The carrier status did not provide any prognostic value
for the eﬀect of shunt surgery in either population. Moreover, no diﬀerence was detected in the
prevalence of hypertension or T2DM between SFMBT1 copy number loss carriers and
noncarriers.
Conclusions
This is the largest and the ﬁrst multinational study reporting the increased prevalence of the
copy number loss in intron 2 of SFMBT1 among patients with iNPH, providing further
evidence of its role in iNPH. The pathogenic role still remains unclear, requiring further study.
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Idiopathic normal pressure hydrocephalus (iNPH) is a late-
onset progressive neurologic disease presenting typically with
gait diﬃculties together with enlarged ventricles and tight-
ened parasagittal cortical sulci, whereas other symptoms such
as cognitive impairment and urinary incontinence are often
present.1,2 Recently, the 2 available diagnostic guidelines1,2
have been criticized, and urgent revision and/or uniﬁcation of
the diagnostic manual have been requested.3–5
Patients with iNPH are characterized by abnormal CSF
circulation and evidence of delayed cerebral clearance, as
recently shown in an MRI CSF tracer study.6 Although
there are no biomarkers to aid in the diagnostics, and the
etiology of iNPH remains unclear, there is an increasing
amount of proof indicating a potential genetic component
in iNPH.7–12 The prevalence of familial iNPH, i.e., at least
2 patients with iNPH, in the ﬁrst-degree relatives has
been reported to range from 4.8% to 7%.10,11 Data also
contain a pair of identical twins having iNPH11 and a family
in which an autosomal dominant inheritance pattern is
observed.9
A segmental copy number loss in the SFMBT1 gene was
reported in Japan to be present in 50% of patients, who
present concomitantly with clinical features of iNPH and
enlarged ventricles,13 and in 26% of patients with iNPH, who
experienced a positive shunt response.14 These results have
previously not been conﬁrmed outside of Japan and with
suﬃciently large cohorts. Our aim was to evaluate the prev-
alence of the copy number loss of SFMBT1 in patients with
iNPH of Caucasian origin.
Methods
Standard protocol approvals, registrations,
and patient consents
This study was conducted in the Department of Neurosurgery
in Kuopio University Hospital, the Brain Research Unit of the
University of Eastern Finland, and the Department of Neu-
rosurgery, Oslo University Hospital, Rikshospitalet, Oslo,
Norway, according to the Declaration of Helsinki. Kuopio
University Hospital Research Ethics Board approved the
study (5/2008 and 276/2016). In Norway, the study was
approved by the Regional Committee for Medical and Health
Research Ethics (REK) of Health Region South-East, Norway
(2015/1313), and the Institutional Review Board of Oslo
University Hospital (2015/8128).
The study consisted of 567 Finnish (mean age 70 years; SD
8.3; men: n = 254; table 1) and 377 Norwegian (mean age
68 years; SD 11; men: n = 190 (50%); table 2) patients with
possible iNPH. All patients and controls provided their written
informed consent.
All Finnish andNorwegian patients suspected of having iNPH
have been clinically evaluated by a neurologist and a neuro-
surgeon. The patients were referred to a neurosurgeon by
a neurologist if the patients were observed to have at least
one of the core symptoms associated with iNPH, which
include gait diﬃculties, cognitive impairment, and urinary
incontinence together with enlarged ventricles (Evans Index
>0.30)15 disproportionate to the size of the sulci of the ce-
rebral convexities in MRI or CT imaging scans. In addition,
most Finnish and Norwegian patients have undergone, as
a prognostic test for shunt beneﬁt, a 24-hour intraventricular
pressure monitoring, spinal tap, extended lumbar drainage,
or lumbar infusion test.
The Norwegian patients were diagnosed, and the decision
to perform the shunt surgery was done following a pre-
viously published protocol,16 which included a clinical
judgment of the severity of iNPH symptoms using a Oslo
iNPH Grading Scale (ranging from 3 to 15),16 MRI or CT
imaging scans for the evaluation of the ventriculomegaly,
evaluation of comorbidities, and ﬁnally a diagnostic over-
night ICP monitoring.
All the Finnish and Norwegian patients fulﬁlled the clinical
diagnostic criteria for possible iNPH.1,2 The control group
consisted of 508 (mean age 70 years; SD 5.1; male: n = 207)
Finnish subjects acquired for neurogenetic studies. All
subjects have undergone clinical and neuropsychological
Table 1 Clinical characteristics of the Finnish iNPH cohort
Variables Mean or no. of cases SD or %
Cases 567
Sex (female) 312 54.9
Comorbidities
High arterial blood pressure 339/564 59.7
Diabetes 169/565 29.8
Age at shunta 71 7.9
Positive subjective shunt
responseb
458/528 86.8
Positive objective shunt responsec 97/203 49
a Available for 551 patients.
b Clinical evaluation at 3-month follow-up.
c Calculated using the modified 12-point Kubo scale, in which 1-point de-
crease is considered to be clinically important.
Glossary
CI = conﬁdence interval; iNPH = idiopathic normal pressure hydrocephalus; OR = odds ratio.
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testing lead by an experienced neurologist specialized in
neurodegenerative conditions to exclude any signs of
cognitive impairment (table 3).
Genomic DNA was extracted from venous blood samples
using QIAamp DNA blood mini extraction kit (QIAGEN).
The copy number loss/gain in the intron 2 region of SFMBT1
was detected using quantitative PCR (qPCR) and the delta-
delta method as previously described.14 Our collaborator (T.
Kato) provided a positive control sample, and a commercial
negative control was used.
All statistical analyses were performed using SPSS statistic
version 23 (IBM corp. USA). The χ2 test was used for cate-
gorical dichotomous variables for groups >2. The Fisher exact
test was used for pairwise comparison. p < 0.05 was consid-
ered statistically signiﬁcant.
Power calculations were completed before the execution of
the research and were based on the results of the study by Sato
et al.14 in which the expected prevalence was divided by
a factor of 2 (26/2% = 13%). With a power of 0.85, p = 0.05,
the sample size was determined to be n ≥ 362. Both the
Finnish and Norwegian iNPH cohorts and Finnish controls
fulﬁll this requirement.
Data availability statement
According to Finnish law, the full individual clinical data set
cannot be shared publicly. However, the data set can/will be
shared by academic collaboration agreement upon request.
Results
The copy number loss in SFMBT1 was detected in 9.9% of
the Finnish patients with iNPH, in 21% of the Norwegian
patients with iNPH, and in 5.4% of the Finnish controls
(ﬁgures 1 and 2). Statistically signiﬁcant diﬀerence was
detected between Finnish and Norwegian patients with
iNPH (p < 0.0001). No copy number gains in SFMBT1 were
detected in Finnish or Norwegian patients with iNPH or
healthy controls. In the Finnish iNPH cohort, 9/71 sus-
pected familial patients, who are carriers for the copy num-
ber loss, were detected, and therefore, no aggregation of the
copy number loss variant was observed in familial iNPH
(12.1% vs 10%, p = 0.5). There was no signiﬁcant diﬀerence
in age at onset, sex, shunting prevalence, or shunt response
between Finnish and Norwegian patients. In addition, no
diﬀerence was detected in the prevalence of hypertension or
T2DM between SFMBT1 copy number loss carriers and
noncarriers (table 4) or in the frequency of the genetic var-
iant between shunt-responsive and nonresponsive patients in
either Finnish (odds ratio [OR] = 1.0, conﬁdence interval [CI]
95% 0.44–2.4, p = 0.93) or Norwegian (OR = 0.68, CI 95%
0.31–1.5, p = 0.33) cohort.
Discussion
This is the ﬁrst study on the prevalence of the copy number
loss in SFMBT1 among patients with iNPH of non-Asian
origin. Although there are studies describing familial aggre-
gation11 and even in some rare cases autosomal dominant
inheritance pattern,9 SFMBT1 is the ﬁrst gene to be associated
with iNPH. Our ﬁndings are principally in line with the Jap-
anese results providing compelling further evidence on the
role of the copy number loss in SFMBT1 in iNPH.
The copy number loss in SFMBT1 is detected only in
10%–20% of the patients with iNPH, which would suggest that
iNPH has both a polygenetic and multifactorial origin. Eth-
nicity seems to modify the prevalence of this genetic variant
between Finnish and Norwegian iNPH patients but surpris-
ingly is similar between selected Norwegian and Japanese
populations. In addition, a small percentage of cognitively in-
tact controls carry the genetic variant providing further evi-
dence on the copy number loss in SFMBT1 of being only
a possible risk-increasing genotype. In the Japanese study,
a small percentage of patients and controls were found to carry
a copy number gain variant, but no statistically signiﬁcant dif-
ference between patients with iNPH and controls was detec-
ted.14 Of interest, in the Nordic cohorts, no copy number gain
variants were detected in either patients with iNPH or healthy
controls. Therefore, it appears that the copy number loss in
Table 2 Clinical characteristics of the Norwegian iNPH
cohort
Variables Mean or no. of cases SD or %
Cases 377
Sex (female) 187/377 49.6
Shunt 297/377 78.8
Comorbidities
Arterial hypertension 156/377 41.4
Diabetes 58/377 15.4
Age at shunt 69 9.9
Positive shunt responsea 258/297 86.95
No shunt response 39/297 13.1
Lost to follow-up 7/297 2.4
Abbreviation: iNPH = idiopathic normal pressure hydrocephalus.
a Clinical evaluation at 6–12months after surgery. Calculated using the Oslo
NPH scale.16
Table 3 Finnish control characteristics
Variables Mean or no. of cases SD or %
Controls 508
Sex (female) 301 59.3
Age at inclusion 69.8 5.1
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SFMBT1 is associated with iNPH, and the results are not
inﬂuenced by genomic instability in the SFMBT1 intron region.
Hypertension, T2DM, schizophrenia, and Alzheimer disease
are common among patients with iNPH.17–22 The present
results could reﬂect a higher occurrence of hypertension and
T2DM in iNPH, as previously demonstrated. However, in
this study cohort, we found no statistically signiﬁcant diﬀer-
ence in the prevalence of hypertension or T2DM between
SFMBT1 copy number loss carriers and noncarriers, further
validating its independent association with iNPH.
In the present study, both shunt-responsive and nonresponsive
patients were included, and no diﬀerence was observed between
these groups regarding the carrier status of the copy number loss
in SFMBT1. The original discovery was done in subjects with
enlarged brain ventricles,13 and the Japanese study on copy
number loss in SFMBT114 included only shunt-responsive iNPH
patients, and therefore, the prevalence of the copy number loss in
SFMBT1 among patients who are nonresponsive to shunt sur-
gery is unknown in the Japanese population.14 Because of the
similar prevalence between both shunt-responsive and non-
responsive patient groups, SFMBT1 seems to be linked with
enlargement of brain ventricles but not with shunt response.
The diagnosis of iNPH is presently based on typical clinical
characteristics and radiologic presentation. In addition, diﬀerent
prognostic tests are used to evaluate the potential shunt beneﬁt,
but no biomarkers have been found to help in the diﬀerential
diagnostics. The current vague diagnostic criteria of iNPH1,2
should be noted in the interpretation of the current results and
further genetic studies on iNPH. These include the deﬁnition of
the diagnosis, heterogeneity of the disease course and variable
radiologic features, and common comorbid neurodegenerative
diseases.4 This poses a challenge for the diﬀerential diagnostics
of iNPH, and both false and missed diagnoses are likely to be
common. Potentially, the genetic information could, in the fu-
ture, be included in diﬀerent risk calculators (e.g., reference 23)
to provide clinician tools that help decide referrals concerning
these types of uncommon diseases.
Figure 1 Flowchart of the study cohort
Flowchart showing the Finnish and
Norwegian cohorts. No difference was
detected between the frequency of the
genetic variant between shunt-re-
sponsive and nonresponsive patients
in either Finnish (OR = 1.0, CI 95%
0.44–2.4, p = 0.93) or Norwegian (OR =
0.68, CI 95% 0.31–1.5, p = 0.33) cohort.
aLost to follow-up (n = 7). bLost to fol-
low-up response (n = 63). CI = confi-
dence interval; OR = odds ratio.
Figure 2 The prevalence of the copy number loss in the
SFMBT1 among Finnish and Norwegian patients
with iNPH
The prevalence of the copy number loss in SFMBT1 among Norwegian iNPH
patients is 21% (n = 79/377), 9.9% (n = 56/567) among Finnish iNPH patients,
and 5.4% (n = 27/508) among Finnish controls. Statistical significance was ob-
served; Norwegian iNPH patients vs Finnish controls (OR = 4.7, CI 95% 3.0–7.5,
p<0.001), Finnish iNPHpatients vs Finnish controls (OR=1.9, CI95%1.2–3.1,p=
0.0078), and Norwegian iNPH patients vs Finnish iNPH patients (OR = 2.5,
CI 95% 1.7–3.6, p < 0.001). p < 0.05 was considered statistically significant. The
Fisher exact test was used for pairwise comparisons. CI = confidence interval;
iNPH = idiopathic normal pressure hydrocephalus; OR = odds ratio.
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The SFMBT1 locus has been previously identiﬁed to be in-
volved in elevated serum urate levels, fasting glucose, and high
blood pressure.24–26 The physiologic role of the SFMBT1
protein is poorly understood but relates to histone binding and
is involved in diﬀerent transcription corepressor activities.27,28
However, the SFMBT1 protein seems to be present in ana-
tomical structures involved with CSF development and circu-
lation such as the choroid plexus, the ependymal cell lining of
the ventricles, and the smooth muscle and endothelial cells
of the arteries.13 A CSF tracer study has revealed disturbed
CSF circulation and delayed CSF tracer clearance within
the brains of patients with iNPH.6 An increasing body of
evidence links the pathophysiology behind iNPH to pro-
cesses taking place at the glia-vascular interface. It has been
shown that patients with iNPH showed evidence of alter-
ations in the brain capillary ultrastructure, including alter-
ations in pericytes and endothelial cells.29 Furthermore, the
perivascular expression of the water channel aquaporin-4
(AQP4) was reduced in iNPH.30
Our study has considerable strengths including a well-
characterized large multinational cohort consisting of both
shunted and nonshunted patients. The most substantial
limitation in the current study is that no healthy Norwegian
control individuals were available and that no internal
validation was used. The prevalence of the copy number
variant could be diﬀerent among neurologically healthy
population. In addition, in the current study, asymptomatic
ventriculomegaly was not routinely evaluated from the
healthy Finnish controls. Therefore, it is possible that the
some of the healthy controls that are carriers for the copy
number loss variant in SFMBT1 have enlarged ventricles
but are asymptomatic. This might skew the current result,
and the association between iNPH and the copy number
loss in SFMBT1 could be even stronger than reported. Al-
though a strong association between the copy number loss in
SFMBT1 and iNPH was found in both the Japanese and the
Caucasian cohorts, there are still limitations to the studies
concentrating on the copy number loss in SFMBT1 and iNPH.
First, no nationwide data exist on the prevalence of the copy
number loss in SFMBT1, and therefore, the controls used
provide only a rough estimation of the prevalence in the normal
population. Second, the role of the SFMBT1 gene in the de-
velopment of cardiovascular diseases needs to be investigated
in depth. In addition, the role of SFMBT1 should be studied in
other neurodegenerative diseases to ﬁnd whether the genetic
variation in SFMBT1 is unique to iNPH. Third, the present
results need still to be conﬁrmed in largermultinational cohorts
both in cross-sectional and prospective study settings.
Normal pressure hydrocephalus is divided into 3 diﬀerent
groups: idiopathic, where the etiology is unclear, secondary
when there is a predisposing factor to be found, and most
recently detected familial type, where iNPH is seen also in the
ﬁrst-degree relatives.9,11 So far, no diﬀerence in the phenotype
has been observed between iNPH and familial NPH. Because
copy number variation of SFMBT1 was not enriched in fa-
milial iNPH, it does not seem to explain familial aggregation
of iNPH, and therefore, other genetic variations are expected
to associate with iNPH. The eﬀect of the copy number loss in
SFMBT1 to the clinical phenotype should be described. This
might shed light into the diﬀerent forms of iNPH with so far
undistinguishable phenotypes.
It has been reported that some of the asymptomatic people
with ventriculomegaly are carriers for the copy number loss in
SFMBT1.13 Ventriculomegaly is a key radiologic ﬁnding in
iNPH, and Evans Index >0.3 is included as a requirement in the
diagnostic criteria of iNPH,1,2 although it has been recently
suggested that the cutoﬀ value for ventricular enlargement
should be age and sex dependent and the pathologic lower limit
of Evan’s Index increased to >0.32.31 It has been suggested that
people who are asymptomatic with enlarged ventricles are at an
increased risk of developing iNPH, and it has been reported
Table 4 Prevalence of hypertension and diabetes
Finnish iNPH patients Norwegian iNPH patients
SFMBT1
carrier, n (%)
SFMBT1 noncarrier,
n (%)
p Value
(CI 95%)
SFMBT1
carrier, n (%)
SFMBT1 noncarrier,
n (%)
p Value
(CI 95%)
Hypertensiona
Yes 29 (52) 309 (61) NS (0.4–1.2) 31 (39) 125 (42) NS (0.5–1.5)
No 27 (48) 198 (39) 48 (61) 173 (58)
Diabetesb
Yes 12 (21) 156 (31) NS (0.3–1.2) 10 (13) 48 (16) NS (0.4–1.6)
No 43 (77) 356 (69) 69 (87) 250 (84)
Abbreviations: CI = confidence interval; iNPH = idiopathic normal pressure hydrocephalus.
NS: nonsignificant p > 0.05.
p values are calculated using the Fisher exact test without correction for multiple testing.
a Data missing from 4 Finnish patients.
b Data missing from 3 Finnish patients.
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that in the Japanese population, 25% of people with asymp-
tomatic ventriculomegaly will eventually develop iNPH.32
However, the cohort sizes have been limited in the studies in
which the connection between AVIM and iNPH has been
proposed. Therefore, no universal consensus on this matter
exists.
The prevalence of the copy number loss in SFMBT1 could be
increased among the families in which iNPH is frequently
observed, and therefore, ﬁrst-degree relatives of patients with
iNPH should be included in future genetic studies. It might be
that the copy number loss in SFMBT1 is a risk gene for iNPH
but requires other unknown triggering risk factors to result in
clinical disease.
Future studies are still urgently needed to elucidate the ge-
netics of iNPH. Understanding even some of the pathologic
processes causing iNPH provides possibilities to develop
targeted or even preventive therapies in the future. This study
encourages functional studies on SFMBT1 to clarify the role
in the disease process of iNPH.
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